HALO
HALO
US40637H1095
Halozyme Therapeutics, Inc.
Loading chart...

Financials

Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
Breakdown 2025 2024 Change %
Total Revenue 1.396.611.000 1.015.324.000
37.6%
Cost of Revenue 228.774.000 159.417.000
43.5%
Gross Profit -- 855.907.000
--
365.244.000 304.432.000
20.0%
Operating Income 802.593.000 551.475.000
45.5%
Pretax Income 466.875.000 557.132.000
16.2%
Net Income Common Stockholders 316.889.000 444.091.000
28.6%
-- --
--
-- --
--
ende